Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study

Min Ji Jeon; Won Gu Kim; Tae Hyuk Kim; Hee Kyung Kim; Bo Hyun Kim; Hyon-Seung Yi; Eun Sook Kim; Hosu Kim; Young Nam Kim; Eun Heui Kim; Tae Yong Kim; Sun Wook Kim; Ho-Cheol Kang; Jae Hoon Chung; Young Kee Shong; Won Bae Kim

doi:10.3803/EnM.2017.32.4.434

Articles

Page Path: HOME > Endocrinol Metab > Volume 32(4); 2017 > Article

Original Article Clinical Study Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study Audioslide: Min Ji Jeon¹, Won Gu Kim¹, Tae Hyuk Kim², Hee Kyung Kim³, Bo Hyun Kim⁴, Hyon-Seung Yi⁵, Eun Sook Kim⁶, Hosu Kim^2,7, Young Nam Kim², Eun Heui Kim⁴, Tae Yong Kim¹, Sun Wook Kim², Ho-Cheol Kang³, Jae Hoon Chung², Young Kee Shong¹, Won Bae Kim¹, on behalf of the Korean Thyroid Cancer Study Group; Endocrinology and Metabolism 2017;32(4):434-441.
DOI: https://doi.org/10.3803/EnM.2017.32.4.434
Published online: November 22, 2017

4,983 Views
53 Download
26 Crossref
28 Scopus

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

²Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

³Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.

⁴Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

⁵Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.

⁶Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

⁷Division of Endocrinology, Department of Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea.

Corresponding author: Won Bae Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: +82-2-3010-3913, Fax: +82-2-3010-6962, kimwb@amc.seoul.kr

Korean Thyroid Cancer Study Group (KTCSG): Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, and Won Bae Kim (Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul); Hosu Kim, Young Nam Kim, Tae Hyuk Kim, Sun Wook Kim, and Jae Hoon Chung (Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul); Hee Kyung Kim and Ho-Cheol Kang (Department of Internal Medicine, Chonnam National University Medical School, Gwangju); Eun Heui Kim, Bo Hyun Kim, and In Joo Kim (Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan); Hyun-Seung Yi, Kun Soon Kim, and Minho Shong (Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon); Eun Sook Kim (Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan); and Eun Kyung Jang and Eui Young Kim (Department of Endocrinology, Dongnam Institute of Radiological & Medical Sciences Cancer Center, Busan, Korea).

• Received: May 24, 2017 • Revised: August 19, 2017 • Accepted: September 15, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGMENTS
Article information
SUPPLEMENTARY MATERIAL
References

ABSTRACT

Background
Little is known regarding disease-specific mortality of differentiated thyroid cancer (DTC) patients and its risk factors in Korea.
Methods
We retrospectively reviewed a large multi-center cohort of thyroid cancer from six Korean hospitals and included 8,058 DTC patients who underwent initial surgery between 1996 and 2005.
Results
Mean age of patients at diagnosis was 46.2±12.3 years; 87% were females. Most patients had papillary thyroid cancer (PTC; 97%) and underwent total thyroidectomy (85%). Mean size of the primary tumor was 1.6±1.0 cm. Approximately 40% of patients had cervical lymph node (LN) metastases and 1.3% had synchronous distant metastases. During 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred; the 10-year disease-specific survival (DSS) rate was 98%. According to the year of diagnosis, the number of disease-specific mortality was not different. However, the rate of disease-specific mortality decreased during the study period (from 7.7% to 0.7%). Older age (≥45 years) at diagnosis, male, follicular thyroid cancer (FTC) versus PTC, larger tumor size (>2 cm), presence of extrathyroidal extension (ETE), lateral cervical LN metastasis, distant metastasis and tumor node metastasis (TNM) stage were independent risk factors of disease-specific mortality of DTC patients.
Conclusion
The rate of disease-specific mortality of Korean DTC patients was 1.9%; the 10-year DSS rate was 98% during 1996 to 2005. Older age at diagnosis, male, FTC, larger tumor size, presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stages were significant risk factors of disease-specific mortality of Korean DTC patients.
Keywords: Mortality; Risk factors; Thyroid neoplasms

INTRODUCTION

The incidence of thyroid cancer has increased worldwide and it is currently the most common cancer among Korean women [1]. Differentiated thyroid cancer (DTC), particularly papillary thyroid cancer (PTC) is the prominent pathologic subtype of thyroid cancer and accounts for the increasing incidence of thyroid cancer. Despite the increase in incidence, disease-specific mortality of thyroid cancer patients is low [2]; a recent study reported that the age-standardized mortality rate of thyroid cancer in Korea ranged from 0.19 to 0.67 per 100,000 individuals between 1985 and 2010 [3].

Although DTC is an indolent cancer with excellent prognosis, identifying the risk factors that predict DTC-related mortality is important. According to previous studies, older age, male sex, and tumor node metastasis (TNM) staging system by the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) were prognostic determinants of DTC-specific mortality [4 5 6 7]. Furthermore, the presence of lymphovascular invasion or extranodal extension of the tumor was associated with mortality of PTC patients [8 9]. Molecular-based approaches demonstrated that the presence of the coexistence of telomerase reverse transcriptase (TERT) promoter and BRAF mutation is associated with mortality of PTC patients [10 11 12 13]. However, no multicenter study has evaluated the risk factors of disease-specific mortality of DTC patients in Korea.

This study aimed to evaluate the trends of disease-specific mortality of DTC patients in Korea using a large multicenter thyroid cancer cohort. We also analyzed the risk factors of disease-specific mortality of DTC patients in Korea.

Study population: In this multi-center, retrospective cohort study, we reviewed the medical records of DTC patients who underwent their initial thyroid surgery between 1996 and 2005 at the following six hospitals in Korea: Asan Medical Center, Samsung Medical Center, Chonnam National University Hwasun Hospital, Pusan National University Hospital, Ulsan University Hospital, and Chungnam National University Hospital. We initially screened 8,360 DTC patients including those with PTC and follicular thyroid cancer (FTC). However, we excluded patients with <1-year follow-up or those with inadequate pathologic reports. Finally, 8,058 patients were eligible for the study.; We analyzed the incidence of disease-specific mortality of the patients and evaluated the patient age at diagnosis of DTC (≥45 years), sex, size of primary tumor (>2 cm), presence of extrathyroidal extension (ETE) of primary tumor, cervical lymph node (LN) metastasis, distant metastasis, and TNM stage on the basis of the 7th edition of the AJCC/UICC TNM staging system [14] as potential risk factors of disease-specific mortality. Our study protocol was approved by the Institutional Review Board of each institution (Asan Medical Center, 2016-1301; Samsung Medical Center, 2016-05-053; Chonnam National University Hwasun Hospital, CNUHH-2017-053; Pusan National University Hospital, 1701-014-051; Ulsan University Hospital, 2016-12-031; and Chungnam National University Hospital, CNUH 2017-01-018). Informed consent was waived due to retrospective design.
Statistics: R studio (version 3.4.0) and the R libraries survival, car, and gdata were used to analyze the data in this study (R Foundation for Statistical Computing, http://www.R-project.org/). Continuous variables are presented as mean±standard deviation, and categorical variables are presented as number (percentage). The chi-square test was used to compare variables according to the year of initial diagnosis. A Cox proportional hazard model was used to evaluate the risk factors of disease-specific mortality. Hazard ratios with 95% confidence intervals were also estimated. Disease-specific survival (DSS) curves was constructed using the Kaplan-Meier method with GraphPad Prism version 5.01 (GraphPad Software Inc., San Diego, CA, USA) and the log rank test was used to evaluate the differences in DSS on the basis of TNM stages. DSS was defined as the time interval between initial surgery and the last censoring or DTC-related death. All P values were two-sided, and P values of <0.05 were considered to be statistically significant.

Baseline characteristics: Table 1 shows the baseline characteristics of 8,058 DTC patients. The mean age of the patients at initial DTC diagnosis was 46.2±12.3 years, and 87% of patients were females. Approximately 85% of patients (n=6,831) underwent total thyroidectomy as the initial surgery and 5,837 patients (72%) underwent radioactive iodine ablation therapy. Most patients had PTC (7,780 patients, 97%) including its variants. The mean size of the primary tumor was 1.6±1.0 cm and 3,960 patients (49%) had ETE of the tumor. Cervical LN metastases were found in 3,218 patients (40%) including 865 patients (11%) with lateral cervical LN metastasis (N1b according to the 7th TNM staging system). At initial diagnosis, 108 patients (1.3%) had synchronous distant metastases. Based on the TNM staging system, 4,992 (72%), 196 (2%), 2,288 (28%), and 575 (7%) patients were classified into stage I, II, III, and IV, respectively.; When we evaluated the baseline characteristics according to the year of initial diagnosis, DTCs diagnosed after 2000 was more likely to be PTCs and were smaller with less LN metastasis compared to DTCs diagnosed before 2000 (Table 2).
Time trends of disease-specific mortality of DTC patients: During 11.3 years of follow-up (interquartile range, 9.1 to 13.0), there were 309 mortality cases (3.8%) including 150 cases (1.9%) of disease-specific mortality. These 150 cases composed of 114 PTCs (76%) and 36 FTCs (24%) (Fig. 1A). Disease-specific mortality occurred at a median of 5.5 years after the initial surgery, and 29 patients (19%) were dead 10 years after the initial surgery. There were no significant differences in the characteristics according to the duration from the initial surgery to mortality event (Supplemental Table S1). The 5-, 10-, and 20-year DSS rates were 99%, 98%, and 94%, respectively (Fig. 2A). Fig. 1 shows the time trends of disease-specific mortality of DTC patients. On the basis of the year of initial DTC diagnosis, the number of disease-specific mortality cases was steady from 1996 to 2005, ranging from 10 to 21 cases each year (Fig. 1B). The incidence of disease-specific mortality decreased from 7.7% in 1997 to 0.7% in 2005 (Fig. 1C).
Risk factors of disease-specific mortality of DTC patients: To evaluate the risk factors for disease-specific mortality of DTC patients, we used a Cox-proportional hazard model. In univariate analysis, older age (≥45 years) at diagnosis, male, FTC, larger tumor size (>2 cm), presence of ETE, lateral cervical LN metastasis (N1b disease), distant metastasis, and TNM stage were significantly associated with disease-specific mortality of DTC patients. In multivariate analysis, all these factors were independent risk factors of disease-specific mortality of DTC patients. TNM staging was an independent risk factor of disease-specific mortality of DTC. No significant differences were found in the risk of disease-specific mortality between stage I and III (Table 3). Fig. 2B shows DSS curves based on the 7th edition of the TNM staging system and DSS was significantly different (P<0.001).

DISCUSSION

This is the first large multicenter cohort study to evaluate disease-specific mortality of 8,058 DTC patients in Korea. During the median of 11.3 years of follow-up, 150 patients (1.9%) died because of DTC, and the 10-year DSS rate was 98%. There were no significant changes in the number of disease-specific mortality with regard to the year of DTC diagnosis. Disease-specific mortality rates of DTC patients decreased during the study period. This trend and characteristics of disease-specific mortality of thyroid cancer patients was similar to that reported in the USA, which analyzed the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results [6] and suggested a recent increase in the incidence of small, low-risk DTCs.

TNM staging according to the 7th edition of the TNM staging system was significantly associated with disease-specific mortality of DTC patients in our subjects [5 15]. Similar to previous studies [4 7 16], older age at diagnosis (≥45 years) was identified as an independent risk factor for disease-specific mortality of DTC patients in this study. Many studies suggested patient age to be a prognostic factor of disease-specific mortality of DTC patients. However, the age cutoff point is controversial. A recent study suggested that patient age was significantly and linearly associated with disease-specific mortality of PTC patients [4], and several studies suggested that a patient age of 55 years is more appropriate than 45 years for the cutoff point [17 18]. On the basis of these studies, the revised 8th edition of the AJCC/UICC TNM staging system changed the cutoff point of patient age from 45 years to 55 years [19]. In our subjects, patient age cutoff point of 55 also significantly differentiates the risk of disease-specific mortality of DTC patients. The diseasespecific mortality rate was 0.56% in younger patients (<55 years) and 5.89% in older patients (≥55 years).

Even though the 7th TNM staging system was associated with disease-specific mortality of DTC patients in this study, there were no significant differences in the risk of mortality of DTC patients between stage I and III. It is because the presence of minimal ETE up-staged small DTCs from T1 to T3 and classified them to stage III according to the 7th TNM staging system [14 20]. Recent studies presented the similar clinical outcomes of DTC patients with or without minimal ETE [21 22] and the revised 8th edition of the TNM staging system also changed the definition of T3 [19]. This new TNM staging system will be used from January 2018. Further studies are required to analyze the impact of altered cutoff point of patient age or the definition of T3 on disease-specific mortality of DTC patients in Korea.

In this study, male, larger tumor (>2 cm), presence of ETE, lateral cervical LN metastases, and distant metastases were significantly associated with disease-specific mortality of DTC patients, and these results are consistent with those previously reported [6 16]. In this study, FTC was also associated with a high risk of disease-specific mortality after adjusting for other risk factors compared with PTC. A previous study reported that FTC had similar mortality rates with PTC after excluding patients with distant metastases at diagnosis [7]. Our findings regarding FTC could be biased owing to relatively higher PTC incidence in Korea. More studies are required to evaluate the long-term outcomes of FTC compared with those of PTC.

Our study has some limitations. In this study, we could not evaluate the impact of lymphovascular invasion or extranodal extension on DTC-related mortality because of the lack of pathology data. We also could not evaluate the mutational profile of DTC on disease-specific mortality. Disease-specific mortality could be underestimated, owing to relatively short follow-up durations in this study. The median follow-up duration of our study subjects was 11.3 years. Disease-specific mortality occurred in a median of 5.5 years after the initial surgery, and 20% occurred 10 years after the initial surgery. Our study took advantage of a large, multicenter cohort of DTC in Korea to minimize selection bias.

In conclusion, the rate of disease-specific mortality of Korean DTC patients who were diagnosed DTC between 1996 and 2005 was 1.9%; the 10-year DSS rate was 98%. Older patient age (≥45 years) at diagnosis, male, FTC, larger tumor size (>2 cm), presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stage were significant risk factors of disease-specific mortality Korean DTC patients.

Acknowledgements

ACKNOWLEDGMENTS

This study was supported by the Korean Endocrine Society of EnM Research Award 2016.

Article information

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

SUPPLEMENTARY MATERIAL

Supplemental Table S1

Baseline Characteristics of Differentiated Thyroid Cancer Patients with Disease-Specific Mortality According to the Duration from Initial Diagnosis to Mortality

enm-32-434-s001.pdf

References

1. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016;48:436–450. Article PubMed PMC PDF
2. Holmes D. Thyroid cancer: mortality unaffected by rise in use of imaging tests. Nat Rev Endocrinol 2016;12:560.Article PDF
3. Choi YM, Kim TY, Jang EK, Kwon H, Jeon MJ, Kim WG, et al. Standardized thyroid cancer mortality in Korea between 1985 and 2010. Endocrinol Metab (Seoul) 2014;29:530–535. Article PubMed PMC
4. Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol 2016;34:4415–4420. Article PubMed PMC
5. Pathak KA, Lambert P, Nason RW, Klonisch T. Comparing a thyroid prognostic nomogram to the existing staging systems for prediction risk of death from thyroid cancers. Eur J Surg Oncol 2016;42:1491–1496. Article PubMed
6. Nilubol N, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer 2015;121:1017–1024. Article PubMed
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–428. Article PubMed
8. Pontius LN, Youngwirth LM, Thomas SM, Scheri RP, Roman SA, Sosa JA. Lymphovascular invasion is associated with survival for papillary thyroid cancer. Endocr Relat Cancer 2016;23:555–562. Article PubMed
9. Suh S, Pak K, Seok JW, Kim IJ. Prognostic value of extranodal extension in thyroid cancer: a meta-analysis. Yonsei Med J 2016;57:1324–1328. Article PubMed PMC
10. Kim TH, Kim YE, Ahn S, Kim JY, Ki CS, Oh YL, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer 2016;23:813–823. Article PubMed
11. Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 2017;27:651–660. Article PubMed
12. Sidaway P. Thyroid cancer: BRAF and/or TERT mutations increase mortality. Nat Rev Clin Oncol 2016;13:652.Article PDF
13. Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW, Xing M. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol 2017;3:202–208.Article PubMed
14. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual; 7th ed. New York: Springer; 2010.
15. Hassan A, Razi M, Riaz S, Khalid M, Nawaz MK, Syed AA, et al. Survival analysis of papillary thyroid carcinoma in relation to stage and recurrence risk: a 20-year experience in Pakistan. Clin Nucl Med 2016;41:606–613. Article PubMed
16. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer 2017;77:140–152. Article PubMed
17. Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid 2016;26:373–380. Article PubMed PMC
18. Kim M, Kim YN, Kim WG, Park S, Kwon H, Jeon MJ, et al. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? Clin Endocrinol (Oxf) 2017;86:438–443. Article PubMed
19. Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual; 8th ed. Chicago: Springer International Publishing; 2017.
20. Kim M, Kim WG, Oh HS, Park S, Kwon H, Song DE, et al. Comparison of the seventh and eighth editions of the American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis staging system for differentiated thyroid cancer. Thyroid 2017;27:1149–1155. Article PubMed
21. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 2006;30:780–786. Article PubMed PDF
22. Woo CG, Sung CO, Choi YM, Kim WG, Kim TY, Shong YK, et al. Clinicopathological significance of minimal extrathyroid extension in solitary papillary thyroid carcinomas. Ann Surg Oncol 2015;22(Suppl 3):S728–S733. Article PubMed PDF

Fig. 1

Time trends of disease-specific mortality of differentiated thyroid cancer patients in Korea based upon the year of initial diagnosis. During a median of 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred. (A) Among 150 cases, 114 cases (76%) were papillary thyroid cancers (PTCs) and 36 cases (24%) were follicular thyroid cancers (FTCs). (B) The number of disease-specific mortality was steady and ranged from 10 to 21 cases. (C) The rate of disease-specific mortality decreased during the study period. The blank bar indicates small primary tumors (≤2 cm) and the black bar indicates large primary tumors (>2 cm).

Fig. 2

Disease-specific survival (DSS) curves of Korean differentiated thyroid cancer patients. (A) The 5-, 10-, and 20-year DSS rates were 99%, 98%, and 94%, respectively. (B) DSS was significantly different according to the 7th edition of the tumor node metastasis (TNM) staging system (P<0.001).

Table 1

Baseline Characteristics of Differentiated Thyroid Cancer Patients

Characteristic		No. (%)	Mean±SD
Age, yr			46.2±12.3
	≥45	4,308 (53)	46.2±12.3
Female sex		6,971 (87)
Extent of initial operation
	Lobectomy	1,227 (15)
	Total thyroidectomy	6,831 (85)
RAI ablation therapy (yes)		5,837 (72)
Pathology
	PTC	7,780 (97)
	FTC	278 (3)
Size of primary tumor, cm			1.6±1.0
	≤2	6,059 (75)
	2.1–4.0	1,652 (21)
	>4	347 (4)
Extra-thyroidal extension
	Microscopic	3,707 (46)
	Gross	253 (3)
T stage
	T1	3,277 (41)
	T2	600 (7)
	T3	3,870 (48)
	T4	311 (4)
N stage
	N0/Nx	4,840 (60)
	N1a	2,353 (29)
	N1b	865 (11)
M stage
	M1	108 (1.3)
TNM stage
	Stage I	4,999 (62)
	Stage II	196 (2)
	Stage III	2,288 (28)
	Stage IV	575 (7)

TNM stage was determined using the 7th edition of the American Joint Committee on Cancer TNM staging system.

SD, standard deviation; RAI, radioactive iodine; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; TNM, tumor node metastasis.

Table 2

Pathological Characteristics of Differentiated Thyroid Cancer Patients According to the Year of Initial Diagnosis

Characteristic		Year of initial diagnosis		P value
Characteristic		1996–2000 (n=1,672, 21%)	2001–2005 (n=6,386, 79%)	P value
Pathology				<0.001
	PTC	1,441 (86)	5,904 (92)
	FTC	231 (14)	482 (8)
Size of primary tumor, cm				<0.001
	≤2	984 (59)	5,075 (79)
	2.1–4.0	563 (34)	1,089 (17)
	>4	125 (7)	222 (3)
Extra-thyroidal extension				0.56
	Microscopic	769 (46)	2,938 (46)
	Gross	59 (4)	194 (3)
LN metastasis				<0.001
	N0/Nx	884 (53)	3,956 (62)
	N1a	567 (34)	1,786 (28)
	N1b	221 (13)	644 (10)
TNM stage				<0.001
	Stage I	1,037 (62)	3,962 (62)
	Stage II	71 (4)	125 (2)
	Stage III	418 (25)	1,870 (29)
	Stage IV	146 (9)	429 (7)

P value was evaluated by the chi-square test. TNM stage was determined by the 7th American Joint Committee on Cancer TNM staging system.

PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; LN, lymph node; TNM, tumor node metastasis.

Table 3

Risk Factors of Disease-Specific Mortality of Differentiated Thyroid Cancer Patients

Variable		Univariate analysis			Multivariate analysis #1^a			Multivariate analysis #2^b
Variable		HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Age, yr
	≥45	9.04	5.21–15.68	<0.001	9.68	5.54–16.91	<0.001	3.44	1.44–8.20	0.005
Female sex		0.40	0.28–0.57	<0.001	0.67	0.45–0.97	0.037	0.61	0.42–0.89	0.009
Pathology
	PTC	Ref			Ref			Ref
	FTC	3.20	2.20–4.65	<0.001	2.44	1.56–3.81	<0.001	2.88	1.86–4.46	<0.001
Size of primary tumor, cm
	≤2	Ref			Ref			Ref
	2.1–4.0	3.10	2.13–4.52	<0.001	2.15	1.44–2.78	<0.001	1.82	1.21–2.74	0.004
	>4	12.46	8.33–18.62	<0.001	5.17	3.23–8.29	<0.001	4.63	2.92–7.33	<0.001
Extra-thyroidal extension
	No	Ref						Ref
	Microscopic	2.47	1.67–3.65	<0.001	2.19	1.43–3.35	<0.001	1.90	1.14–3.15	0.014
	Gross	13.73	8.46–22.31	<0.001	4.70	2.68–8.25	<0.001	2.63	1.42–4.89	0.002
LN metastasis
	N0/Nx	Ref			Ref
	N1a	0.79	0.51–1.22	0.28	0.77	0.49–1.22	0.270
	N1b	3.48	2.42–5.02	<0.001	1.81	1.18–2.78	0.007
Distant metastasis
	No	Ref			Ref
	Yes	18.04	12.00–27.10	<0.001	7.55	4.81–11.83	<0.001
TNM stage
	Stage I	Ref
	Stage II	10.60	4.82–23.32	<0.001				2.78	1.07–7.20	0.036
	Stage III	5.27	3.12–8.90	<0.001				1.58	0.67–3.70	0.290
	Stage IV	35.25	21.52–57.73	<0.001				7.21	3.05–17.06	<0.001

TNM stage was determined by the 7th American Joint Committee on Cancer TNM staging system.

HR, hazard ratio; CI, confidence interval; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; LN, lymph node; TNM, tumor node metastasis.

^aIn multivariate analysis #1, we used age at diagnosis, sex, pathology, primary tumor size, presence of extrathyroidal extension, cervical LN metastasis, and distant metastasis as possible risk factors; ^bIn multivariate analysis #2, we used age at diagnosis, sex, pathology, primary tumor size, presence of extrathyroidal extension, and TNM staging as possible risk factors.

Figure & Data

References

Citations

Citations to this article as recorded by

Log odds of negative lymph nodes/T stage ratio (LONT): A new prognostic tool for differentiated thyroid cancer without metastases in patients aged 55 and older
Xuezhen Wang, Yufan Wu, Xiaoxia Li, Jinsheng Hong, Mingwei Zhang
Frontiers in Endocrinology.2023;[Epub] CrossRef
The association between vitamin D supplementation and the long-term prognosis of differentiated thyroid cancer patients: a retrospective observational cohort study with propensity score matching
Jong-hyuk Ahn, Hoonsung Choi, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Do Joon Park, Young Joo Park
Frontiers in Endocrinology.2023;[Epub] CrossRef
Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer
Kyeong Jin Kim, Kyoung Jin Kim, Jimi Choi, Nam Hoon Kim, Sin Gon Kim
JNCI: Journal of the National Cancer Institute.2023; 115(6): 695. CrossRef
Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy
Nicholas L. Kesby, Alexander J. Papachristos, Matti Gild, Ahmad Aniss, Mark S. Sywak, Roderick Clifton-Bligh, Stan B. Sidhu, Anthony R. Glover
Annals of Surgical Oncology.2022; 29(1): 64. CrossRef
Clinical Implication of Mutifocality for Risk of Recurrence in Patients With Papillary Thyroid Carcinoma
Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim
Journal of Endocrine Surgery.2022; 22(1): 10. CrossRef
Clinical Factors Predictive of Lymph Node Metastasis in Thyroid Cancer Patients: A Multivariate Analysis
Hui Zheng, Victoria Lai, Jana Lu, Jin K Kang, Jiling Chou, Kenneth D Burman, Leonard Wartofsky, Jennifer E Rosen
Journal of the American College of Surgeons.2022; 234(4): 691. CrossRef
Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients
Ra-Yeong Song, Hee Sung Kim, Kyung Ho Kang
World Journal of Surgical Oncology.2022;[Epub] CrossRef
Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma
Il Ku Kang, Kwangsoon Kim, Joonseon Park, Ja Seong Bae, Jeong Soo Kim
Cancers.2022; 14(15): 3677. CrossRef
Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma
Pengfei Gu, Yu Zeng, Weike Ma, Wei Zhang, Yu Liu, Fengli Guo, Xianhui Ruan, Jiadong Chi, Xiangqian Zheng, Ming Gao
Frontiers in Endocrinology.2022;[Epub] CrossRef
MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer
Jong-Lyul Park, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, Yong-Sung Kim
Cancers.2021; 13(4): 632. CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
Scientific Reports.2021;[Epub] CrossRef
A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
International Journal of Thyroidology.2021; 14(2): 175. CrossRef
Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma
Eyun Song, Jonghwa Ahn, Dong Eun Song, Won Woong Kim, Min Ji Jeon, Tae‐Yon Sung, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Yu‐Mi Lee, Won Gu Kim
Clinical Endocrinology.2020; 92(4): 358. CrossRef
Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases
Omnia Mohamed Talaat, Ismail Mohamed Ali, Sherif Maher Abolyazid, Bader Abdelmaksoud, Ibrahim Mansour Nasr
Nuclear Medicine Communications.2020; 41(4): 327. CrossRef
Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung
Journal of Pathology and Translational Medicine.2020; 54(4): 310. CrossRef
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
Endocrinology and Metabolism.2020; 35(3): 618. CrossRef
The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice
Krzysztof Kaliszewski, Dorota Diakowska, Łukasz Nowak, Beata Wojtczak, Jerzy Rudnicki
BMC Cancer.2020;[Epub] CrossRef
Lobectomy Is Feasible for 1–4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence
Eyun Song, Minkyu Han, Hye-Seon Oh, Won Woong Kim, Min Ji Jeon, Yu-Mi Lee, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Tae-Yon Sung, Won Gu Kim
Thyroid.2019; 29(1): 64. CrossRef
The binary presence or absence of lymph node metastasis or extrathyroidal extension is not associated with survival in papillary thyroid cancers: Implications for staging systems
Hyun-Soo Zhang, Eun-Kyung Lee, Yuh-Seog Jung, Byung-Ho Nam, Boyoung Park
Cancer Epidemiology.2019; 63: 101589. CrossRef
Risk of Adverse Obstetric Outcomes and the Abnormal Growth of Offspring in Women with a History of Thyroid Cancer
Geum Joon Cho, So-youn Kim, Hoi Chang Lee, Kyu-Min Lee, Sung Won Han, Min-Jeong Oh, Teresa K. Woodruff
Thyroid.2019; 29(6): 879. CrossRef
Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer
Suyeon Park, Min Ji Jeon, Hye-Seon Oh, Yu-Mi Lee, Tae-Yon Sung, Minkyu Han, Ji Min Han, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2018; 28(8): 997. CrossRef
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2018; 33(4): 459. CrossRef
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea
Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung
Endocrinology and Metabolism.2018; 33(2): 287. CrossRef
Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study
Min Ji Jeon, Hee Kyung Kim, Eun Heui Kim, Eun Sook Kim, Hyon-Seung Yi, Tae Yong Kim, Ho-Cheol Kang, Young Kee Shong, Won Bae Kim, Bo Hyun Kim, Won Gu Kim
Thyroid.2018; 28(9): 1121. CrossRef
Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea
Hye-Seon Oh, Jeonghoon Ha, Hye In Kim, Tae Hyuk Kim, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Young Kee Shong, Jae Hoon Chung, Jung Hwan Baek
Thyroid.2018; 28(12): 1587. CrossRef